Jinghua Pharmaceutical announced on October 11 that it recently received a Drug Clinical Trial Approval Notice issued by the National Medical Products Administration. The clinical trial application for its Ji Desheng Snake Tablet to add a new indication for shingles, specifically the liver-gallbladder damp-heat syndrome, has been approved. Ji Desheng Snake Tablet is a marketed traditional Chinese medicine product of the company, with current approved indications being clearing heat and detoxifying, reducing swelling and relieving pain, for use in venomous snake and insect bites.
Nantong Jinghua Pharmaceutical Co LtdJi Desheng Snake Tablet received NMPA clinical trial approval to add a new shingles indication, an R&D/product development for the company.
